Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer‐derived CD133‐positive cells
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) signaling reportedly promotes tumor malignancy and recurrence in nonsmall cell lung cancer (NSCLC). It was demonstrated previously that the STAT3 pathway maintains the tumorigenicity and therapeutic resistance of malignant tumors as well as cancer stem cells (CSCs). The objective of the current study was to investigate the effect of the strong STAT3 inhibitor, cucurbitacin I, in prominin‐1 (CD133)‐positive lung cancer cells. METHODS: CD133‐positive and CD133‐negative NSCLC‐derived cells were isolated from 7 patients with NSCLC. CD133‐positive NSCLC cells that were treated with or without cucurbitacin I were evaluated for their expression of phosphorylated STAT3 (p‐STAT3), tumorigenicity, stemness properties, and resistance to chemotherapeutic drugs and ionizing radiation. RESULTS: Compared with parental or CD133‐negative NSCLC cells, CD133‐positive NSCLC cells had greater tumorigenicity, greater radioresistance, and higher expression of octamer‐binding transcription factor 4 (Oct‐4), Nanog homeobox, and sex‐determining region Y, box 2 (Sox2) at high p‐STAT3 levels. Cucurbitacin I treatment at 100 nM effectively abrogated STAT3 activation, tumorigenic capacity, sphere formation ability, radioresistance, and chemoresistance in CD133‐positive NSCLC cells. Microarray data suggested that cucurbitacin I inhibited the stemness gene signature of CD133‐positive NSCLC cells and facilitated the differentiation of CD133‐positive NSCLC cells into CD133‐negative NSCLC cells. It is noteworthy that 150 nM cucurbitacin I effectively blocked STAT3 signaling and downstream survival targets, such as B‐cell chronic lymphocytic leukemia/lymphoma 2 (Bcl‐2) and Bcl‐2‐like 1 (Bcl‐xL) expression and induced apoptosis in CD133‐positive NSCLC cells. Finally, xenotransplantation experiments revealed that cucurbitacin I plus radiotherapy or chemotherapeutic drugs significantly suppressed tumorigenesis and improved survival in NSCLC‐CD133‐positive‐transplanted, immunocompromised mice. CONCLUSIONS: Targeting STAT3 signaling in CD133‐positive NSCLC cells with cucurbitacin I suppressed CSC‐like properties and enhanced chemoradiotherapy response. The potential of cucurbitacin I should be verified further in future anti‐CSC therapy. Cancer 2011. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 2×
“Oncogenic STAT3 activation leads to the increased expression of downstream genes that suppress apoptosis (B-cell chronic lymphocytic leukemia/lymphoma 2 [Bcl-2]-like 1 [Bcl-xL]), regulate cell cycle progression (p21, c-Myc, and cyclin D1), mediate cellular invasion (matrix metalloproteinase 9 [MMP-9]), and modulate an…”
BackgroundBowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633
Yeh, H.-H., Lai, W.-W., Chen, H. H. W., Liu, H.-S., & Su, W.-C. (2006) · Oncogene · doi:10.1038/sj.onc.1209464 · Cited by 230 · cited 1×
“Constitutively activated STAT3 reportedly was detected in several human lung cancer cell lines and in tumor cells that infiltrated the pleurae of patients who had malignant pleural effusionassociated lung adenocarcinoma.(32) Several reports have indicated the synergistic effect of cucurbitacin with known chemotherapeu…”
Background
Cited by
Zhou, H.-M., Zhang, J.-G., Zhang, X., & Li, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00430-1 · Cited by 472
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
Therapeutic modulators of STAT signalling for human diseases
Miklossy, G., Hilliard, T. S., & Turkson, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4088 · Cited by 413
Terpenoids: natural products for cancer therapy
Huang, M., Lu, J.-J., Huang, M.-Q., Bao, J.-L., Chen, X.-P., & Wang, Y.-T. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.727395 · Cited by 333
Grosse‐Gehling, P., Fargeas, C. A., Dittfeld, C., Garbe, Y., Alison, M. R., Corbeil, D., & Kunz‐Schughart, L. A. (2013) · The Journal of Pathology · doi:10.1002/path.4086 · Cited by 301
Metadata
- Authors
- Hsu, H., Huang, P., Chang, Y., Tzao, C., Chen, Y., Shih, H., Hung, S., Chen, Y., Tseng, L., & Chiou, S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-01-10
- Volume
- 117
- Issue
- 13
- Pages
- 2970-2985
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1987678124
- Cited by
- 112
- References
- 5
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer‐derived CD133‐positive cells. https://app.cochat.ai/papers/10.1002/cncr.25869
- The paper
- Hsu, H., Huang, P., Chang, Y., Tzao, C., Chen, Y., Shih, H., Hung, S., Chen, Y., Tseng, L., & Chiou, S. (2011). Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer‐derived CD133‐positive cells. Cancer. https://doi.org/10.1002/cncr.25869
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.